Viewing data from:

HUMALOG MIX 75/25

BLA

INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT | B021017 | LILLY

3 products0 Purple Book patents

Biologic LOENo LOE data

No exclusivity dates or listed patents found in Purple Book

Purple Book Patents

No listed patents in Purple Book.

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Purple Book (Biologics)

BLA 21017 | 3 presentations

351(a) ReferenceLicensedCDERInjectable Suspension

Proper Name

insulin lispro protamine and insulin lispro

Applicant

Eli Lilly and Company

Approval Date

22-Dec-99

750UNITS/10ML (75UNITS/ML); 250UNITS/10ML (25UNITS/ML) — Multi-Dose Vial (Subcutaneous)

225UNITS/3ML (75UNITS/ML); 75UNITS/3ML (25UNITS/ML) — Autoinjector (Subcutaneous)

Source: FDA Purple Book (purplebooksearch.fda.gov).

Approval Letters

19 letters from Drugs@FDA

Source: Drugs@FDA application documents.

Products (3)

Sort:

#001 — 75 UNITS/ML;25 UNITS/ML

▴

INJECTABLE;INJECTION | Approved: 1999-12-22 00:00:00

No patent or exclusivity listings for this strength.

#002 — 75 UNITS/ML;25 UNITS/ML

▾

INJECTABLE;INJECTION | Approved: 1999-12-22 00:00:00

#003 — 75 UNITS/ML;25 UNITS/ML

▾

INJECTABLE;INJECTION | Approved: 1999-12-22 00:00:00